Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burlando

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 20, 2020
Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasisP Gisondi, F Bellinato, A Conti, et al.
Expert Opinion on Biological Therapy|March 17, 2023
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year studyGiacomo Caldarola, A Chiricozzi, M Megna, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 14, 2020
Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian studyA Dattola, A Balato, M Megna, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 30, 2024
Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis)L Gargiulo, L Ibba, P Malagoli, et al.
The British Journal of Dermatology|December 23, 2018
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experienceA Conti, F Peccerillo, P Amerio, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 23, 2023
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)L Gargiulo, L Ibba, P Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 7, 2023
PsoBioVax: A multicentric Italian case-control study of the immunological response to anti-SARS-CoV-2 vaccine among psoriatic patients under biological therapyL Sacchelli, F Filippi, A Balato, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 26, 2024
Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER studyC Bonifati, S Lembo, A G Richetta, et al.
The Journal of Dermatological Treatment|February 6, 2025
Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis)D Orsini, D Graceffa, M Burlando, et al.
The Journal of Dermatological Treatment|August 20, 2024
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis)D Orsini, M Megna, C Assorgi, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 20, 2020
Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasisP Gisondi, F Bellinato, A Conti, et al.
Expert Opinion on Biological Therapy|March 17, 2023
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year studyGiacomo Caldarola, A Chiricozzi, M Megna, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 14, 2020
Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian studyA Dattola, A Balato, M Megna, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 30, 2024
Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis)L Gargiulo, L Ibba, P Malagoli, et al.
The British Journal of Dermatology|December 23, 2018
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experienceA Conti, F Peccerillo, P Amerio, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 23, 2023
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)L Gargiulo, L Ibba, P Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 7, 2023
PsoBioVax: A multicentric Italian case-control study of the immunological response to anti-SARS-CoV-2 vaccine among psoriatic patients under biological therapyL Sacchelli, F Filippi, A Balato, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 26, 2024
Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER studyC Bonifati, S Lembo, A G Richetta, et al.
The Journal of Dermatological Treatment|February 6, 2025
Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis)D Orsini, D Graceffa, M Burlando, et al.
The Journal of Dermatological Treatment|August 20, 2024
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis)D Orsini, M Megna, C Assorgi, et al.
Pageof 3